Image from bbc.co.uk
FDA Approves Pill Form of Wegovy, Novo Nordisk's GLP-1 Weight-Loss Drug
L 10%
C 85%
R
The FDA has approved a pill form of Wegovy, a GLP-1 weight-loss drug developed by Novo Nordisk. This approval marks Wegovy's first availability as a pill, whereas previously it was only offered as an injection. The once-daily pill provides a convenient alternative and delivers the same weight loss effects as the injectable version. This approval builds on Wegovy's existing FDA indication for weight loss.
Novo Nordisk also produces Ozempic, another GLP-1 drug with similar weight-loss benefits, which is primarily approved for treating Type 2 diabetes. The development of the oral version of Wegovy signals a broader trend toward oral obesity medications and expands treatment options for patients.
The approval was announced on 23 December 2025.
Sources
* This article has been summarised using Artificial Intelligence and may contain inaccuracies. Please fact-check details with the sources provided.